Clinical ResearchA Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure
Presented in part at the American College of Cardiology Annual Meeting, 2015, San Diego, California.
Under a Creative Commons license
open access
Visual Abstract
Key Words
cardiac repair
growth factor
neuregulin
systolic dysfunction
Abbreviations and Acronyms
AE
adverse event
AUC
area under the curve
DLT
dose-limiting toxicity
GGF
glial growth factor
HF
heart failure
LVEF
left ventricular ejection fraction
LVSD
left ventricular systolic dysfunction
NRG
neuregulin
NYHA
New York Heart Association functional class
TEAE
treatment-emergent adverse event
Cited by (0)
This study was funded by Acorda Therapeutics, Inc., Ardsley, New York. Drs. Lenihan and Sawyer are consultants with and have received research funding from Acorda Therapeutics, Inc. Dr. Lenihan has also received support from Takeda, Roche, Bristol-Myers Squibb, Prothena, and Amgen. Dr. Brittain has received funding from Gilead Sciences. Dr. Zolty was an employee of Acorda Therapeutics, Inc., at the time of the study and is now a paid consultant to Acorda Therapeutics, Inc. Ms. Iaci and Drs. Caggiano, Zhao, and Eisen are employed by and own stock in Acorda Therapeutics, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
© 2016 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.